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Fig. 1. Treg cells in liver diseases. (A–C) Identiﬁcation of Treg cells by ﬂow cytometry. (A) Dot plot showing the staining for CD4 and CD25 in T cells gated as CD3+CD4+.
Treg cells are CD4+CD25+ bright. (B) dot plot showing the coexpression of CD25 and FoxP3 in CD4+ T cells. Tregs are CD25+FoxP3+. (C) dot plot showing the coexpression of
CD25 and CD127 in CD4+ T cells. Treg cells are CD25+CD127+ low. Percentages of positive cells are indicated. A minimum of 50,000 live cell events were collected using
FACSCanto ﬂow cytometry (Becton & Dickinson, San Jose, CA, USA) and analyzed with DiVa software (Becton & Dickinson). (D) Statistical analysis of percentages of Treg
cells in controls, AIH and NASH patients. Histograms of mean and standard deviations of percentages of CD4+CD25high and CD25highCD127lowFox3P positive Treg cells in
peripheral blood lymphocytes of 4 healthy controls, 4 AIH, and 4 NASH patients. No statistical difference is observed within the analyzed groups (Mann–Whitney test,
p >0.05).
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IRCCS, Rome, Italyniﬁcantly lower (p <0.01) in children with an NAFLD activity
score (NAS) P5 and ﬁbrosis with respect to children with NAS
<5. Furthermore, our preliminary data in 30 NAFLD children indi-
cates that liver-resident CD25+ cells are rare in this condition (not
shown). These ﬁndings oppose Peiseler et al. [1] when stating
about the presence of FOXP3+ in NASH.
Despite several criticisms, Peiseler’s study and Longhi’s com-
ments raise new questions and provide an experimental break-
through regarding the study of the Tregs frequency and its
function in inﬂammatory liver diseases. The role of the innate
and adaptive immunity in NAFLD/NASH still remains an open
and intriguing issue [10].
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autoimmune hepatitis. J Hepatol 2012;57:932–933.Reply to: ‘‘T regulatory cell number and function: The
autoimmune traits in liver diseases’’To the Editor:
We read with interest the comment of Fierabracci et al. on a
recent discussion between Longhi et al. [1] and us [2] on the fre-
quency of regulatory T cells (Treg) in autoimmune hepatitis
(AIH). This debate was in connection with our recent publication
demonstrating that, in contrast to previous reports, Treg frequen-cies in the blood of AIH patients are not decreased [3]. We gladly
acknowledge that Fierabracci et al. basically conﬁrm our ﬁnding
of unreduced Treg numbers in AIH.
However, the Treg frequencies in blood reported by us are
lower than those previously reported, which has been a matter
of debate between Longhi et al. [1] and us [2]. Fierabracci et al.2 vol. 57 j 1391–1402 1399
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Letters to the Editor
also found higher Treg frequencies in blood than we did, and
explain this as being ‘‘age-related’’; they studied children
whereas we studied adult patients. At that point, we disagree
with Fierabracci et al. as we are convinced that the differences
in Treg frequency are a direct result of the assay-inherent impre-
cision in classifying peripheral blood lymphocytes into the cate-
gories ‘Treg’ and ‘non-Treg’. An ideal assay would fulﬁl such
classiﬁcation task with 100% sensitivity and speciﬁcity. Yet there
is no direct measurement for Treg cells; instead, we have to rely
on surrogate markers, such as CD25 or FoxP3. Because these
markers are compromised, a trade-off between sensitivity and
speciﬁcity occurs, such that they are to some extent inversely
correlated with one another. Previous reports have classiﬁed Treg
and non-Treg according to only one marker, i.e., CD25. Such pro-
tocols have a relatively high sensitivity, but low speciﬁcity.
Therefore, high Treg frequencies are detected, but these include
many false positives. If we apply the same methodology with
our patients, we detect ‘Treg’ with a median of about 9% in AIH
patients with active disease (Fig. 1E in [3]). Fierabracci et al. have
used a combination of two indicators, CD25 and FoxP3 in their
Fig. 1B or, alternatively, CD25 and CD127 in their Fig. 1C. Such
combination results in ‘Treg’ frequencies of about 4%. However,
the combination of two markers for Treg classiﬁcation is still
not very speciﬁc [4]. Moreover, it has been reported that a frac-
tion of only 1–2% of the cells in human blood, i.e., cells with high
CD25 expression, contain cells with suppressive capacity [5].
Thus, a Treg frequency of 4% as determined by Fierabracci et al.
is also overestimated due to inclusion of false positives.
Therefore, we have chosen an approach that relies on a com-
bination of three surrogate markers, i.e., CD25high, FoxP3+, and
CD127low [3]. In contrast to Fierabracci, we have used consecutive
gates, such that we ﬁrst gated on the 1–2% of CD4+CD25high cells,
and used this gate as parent for the analysis of FoxP3+CD127low
cells (Fig. 1A in [3]). Consequently, we detect Treg at frequencies
of only about 0.7% (Fig. 1A in [3]). Although the sensitivity of our
approach is relatively low, the speciﬁcity is very high and we can
be quite certain that we do not count false positives. We feel that
such a high assay speciﬁcity is essential for meaningful compar-
isons of Treg frequencies between patients and healthy subjects,
and even more important for drawing conclusions related to
treatment decisions.
Another comment by Fierabracci et al. relates to the histolog-
ical Treg staining within the inﬂamed liver. Fierabracci et al. refer
to own preliminary data indicating a low intrahepatic frequency
of CD25+ cells in NAFLD children, and conclude that these ﬁnd-
ings seem to oppose ours. We cannot follow this conclusion, since
we also found a lower degree of liver inﬂammation in NASH as
compared to AIH. However, CD25 as a marker is greatly compro-
mised since it equally stains both Treg and activated effector
cells. We used FoxP3 as marker, which is less compromised and
stains Treg with relatively high speciﬁcity [3]. We found a higher
number of FoxP3+ Treg cells in AIH than in NASH livers; however,1400 Journal of Hepatology 2012the proportion of FoxP3+ cells among inﬁltrating CD3+ cells was
not signiﬁcantly increased. This indicated that the intrahepatic
Treg numbers seemed to correlate with the numbers of inﬁltrat-
ing T cells. To conﬁrm this observation, we applied the mHAI
score as an approximate indicator of inﬂammatory activity, and
indeed found that the mHAI score was signiﬁcantly higher in
AIH than in NASH biopsies. Although, as Fierabracci et al. argue,
the mHAI may not be fully appropriate to assess inﬂammatory
activity in NASH, it allowed us to estimate the degree of inﬂam-
mation across diseases; the disease-speciﬁc NAFLD clinical
research network criteria [6] favoured by Fierabracci et al. would
not have allowed such estimation. Nevertheless, our conclusion
that Treg numbers in the inﬂamed liver seem to correlate with
the degree of inﬂammation is in full agreement with recent
reports by Oo et al. [7] and Speletas et al. [8].
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